Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

Sitaxsentan Proves Effective Up to 6 Years for Patients With Severe Pulmonary Arterial Hypertension: Presented at CHEST 2009 By Betty S. Riggs SAN DIEGO -- November 10, 2009 -- Sitaxsentan is effective for long-term therapy of patients with severe pulmonary arterial hypertension (PAH), according to a study presented here on November 3 at CHEST 2009, the annual meeting of the American College of Chest Physicians. Maria-Dolores Hernandez de Diego, MD, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico, and colleagues evaluated the long-term efficacy of sitaxsentan treatment in 54 patients with severe PAH. Patients were enrolled in the Sitaxsentan Sodium Treatment in Patients With Pulmonary Arterial Hypertension (STRIDE-3) study where they were treated with sitaxsentan 100 mg daily for 6 years. At baseline, haemodynamic parameters were assessed; 6-minute walk distance (6MWD), Borg Scale (BS), and World Health Organization Functional Class (WHO FC) were measured every 6 months for 6 years. Patients were divided into groups by etiology. Group 1 included 36 patients with idiopathic PAH (IPAH; 83% female) or PAH-connective-tissue disorders (CTD; 100% female) and group 2 included 18 patients with PAH-congenital systemic-to-pulmonary shunts (CSPS; 93% female). The differences between years for mean 6MWD, BS, and WHO FC were not statistically significant. The mean 6MWD did not deteriorate below baseline levels during the study in either group. The majority of patients entered the study with a WHO FC of class II, and the majority remained class II at the end of the 6 years in both groups. A total of 14 patients died, and 4 patients were initiated on combined therapy with sildenafil. The mean survival for group 1 was 62 months for IPAH patients and 57 months for PAH-CTD patients. Mean survival for group 2 was 73 months. The mean survival difference between groups was statistically significant (P < .05). The cumulative survival percentages at 1, 3, and 6 years were 90%, 81%, and 65% for the IPAH patients; 100%, 72%, and 40% for the PAH-CTD patients; and 100%, 95%, and 95% for the PAH-CSPS patients. [Presentation title: Long-Term Efficacy of Sitaxsentan in Patients With Severe Pulmonary Arterial Hypertension: A Six-Year Follow-Up] E-mail this page to a friend or colleague! To print, use this version